Quality of life in hyperkalemia: baseline analysis of a cohort study of management of hyperkalemia in patients with chronic kidney disease or heart failure in Japan

Background. Hyperkalemia is common in chronic kidney disease (CKD) and chronic heart failure (CHF), often leading to treatment dilemmas regarding renin-angiotensin-aldosterone system (RAAS) inhibitors. Although potassium binders and dietary restrictions are central to chronic management, their quality-of-life (QOL) impact remains insufficiently described. This study aimed to characterize real-world treatment patterns and evaluate treatment impact on QOL. Methods. We analyzed baseline data from a prospective cohort in Japanese nephrology and cardiology outpatient clinics. Participants were adults with CKD ([≥] stage G3) or CHF (New York Heart Association class II-IV) who initiated potassium binders within 6 months. Clinical data, serum potassium values, and patient-reported outcomes (generic QOL, disease/treatment-specific QOL, and adherence measures) were obtained at enrollment. Results. Among 347 patients, the median age was 75 years, and 74% were male; 93% had CKD. At enrollment, 300 patients were receiving potassium binders, and 59% were prescribed a RAAS inhibitor. Dietary therapy was implemented in 29%. Physical scores of generic QOL were lower than population norms, whereas mental scores were comparable. Treatment-specific QOL scores indicated that potassium binders had a smaller impact on QOL than dietary therapy. Adherence to potassium binders was high. Conclusions. Concurrent use of RAAS inhibitors and potassium binders was common, suggesting that binders may support RAAS inhibitor continuation. Potassium binders showed less perceived impact than dietary restrictions, indicating that pharmacologic potassium control may be acceptable to patients managing multiple lifestyle limitations. These findings highlight the role of potassium binders in maintaining both RAAS inhibitor therapy and QOL.